logo BDSP

Base documentaire


  1. Tamoxifen as initial endocrine therapy for metastatic breast cancer : Long term follow-up of two Piedmont Oncology Association (POA) trials.

    Article - En anglais

    Purpose 

    To examine the outcomes of endocrine naive patients treated with tamoxifen as initial endocrine therapy for metastatic breast cancer.

    Data were obtained from the long-term follow-up of two previously published randomized trials.

    Patients and methods 

    All patients received tamoxifen 20 mg po in a single daily dose.

    Eligibility required patients to be age =18, performance status 0-3, and estrogen or progesterone receptor positive or unknown.

    Patients were ineligible if they had any prior endocrine therapy in either the adjuvant or metastatic setting.

    Results 

    156 patients have been followed for a median of 8.3 years.

    Median age was 61 years, 83% were =50 years, 84% performance status of 0-1,43% were both ER and PR positive, 33% had prior chemotherapy, 62% had a disease-free interval of>2 years, and 59% had only one metastatic site.

    The complete (14%) and partial (6%) response rate for 147 evaluable patients was 20% (95% CI for CR+PR of 14-27%). Multivariate analysis revealed that improved response was related to soft tissue involvement and positive PR status.

    The majority of patients with soft tissue, nodal or lung metastases had responses noted within three months.

    Median time to disease progression was 6.7 months.

    Multivariate analysis revealed that older patients, those with one metastatic site and those with positive PR status had the longest time to progression.

    Median survival was 27.2 months. (...)

    Mots-clés Pascal : Tamoxifène, Chimiothérapie, Traitement, Initiation, Tumeur maligne, Glande mammaire, Stade avancé, Homme, Etude longitudinale, Long terme, Voie orale, Femelle, Essai clinique, Epidémiologie, Composé non stéroïde, Antioestrogène, Antihormone, Anticancéreux, Glande mammaire pathologie, Piémont Province, Italie, Europe

    Mots-clés Pascal anglais : Tamoxifene, Chemotherapy, Treatment, Initiation, Malignant tumor, Mammary gland, Advanced stage, Human, Follow up study, Long term, Oral administration, Female, Clinical trial, Epidemiology, Non steroid compound, Antiestrogen, Antihormone, Antineoplastic agent, Mammary gland diseases, Piedmont, Italy, Europe

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0225436

    Code Inist : 002B02R02. Création : 11/06/1997.